BriaCell Therapeutics 

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Earnings data Q2 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

NEW YORK and VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board.

BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board

NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors.

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as it was to lose your favorite restaurant or dry cleaner, imagine the impact of losing a company that had devoted itself to enhancing the lives of women with breast cancer.

BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that its board of directors (the “Board”) has authorized the Company's repurchase program whereby the Company may purchase through the facilities of the TSX Venture Exchange ("TSXV") or The NASDAQ Capital Market ("NASDAQ") (i) up to 1,341,515 common shares (the “Common Shares”) and (ii) up to 411,962 publicly traded BCTXW warrants (the “Listed Warrants”) in total, representing 10% of the 13,415,154 Common Shares and 10% of the 4,119,622 Listed Warrants comprising the "public float" as of September 8, 2021, over the next 12 months (the “Buyback”). Independent Trading Group (ITG) Inc. will act as the Company's advisor and dealer manager in respect of the Buyback. The Company expects to finalize the terms of the Buyback and formally commence the Buyback by September 14, 2021, subject to obtaining any necessary regulatory approvals.

BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces the appointment of Mr. Marc Lustig to the Company's Board of Directors, effective September 1, 2021. Marc, through his investment company L5 Capital Inc., owns 1,530,000 common shares of BriaCell, representing 10.0% of BriaCell's issued and outstanding common shares.

BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors

BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation immuno-oncology imaging agents and radiopharmaceutical therapies. Under the agreement terms, ImaginAb will supply clinical doses of its CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to BriaCell for use in BriaCell's ongoing Phase 1/2a study with Incyte Corporation (NASDAQ: INCY) in metastatic or locally recurrent breast cancer patients.

BriaCell, ImaginAb Join Forces To Assess Imaging Tech In Breast Cancer Trial

BriaCell to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells BriaCell to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer

Photo by Chokniti Khongchum from Pexels In 2020, there were 2.3 million women globally diagnosed with breast cancer and 685,000 deaths, according to the World Health Organization. In the U.S., 12.9% of women born in the country today will develop breast cancer at some time during their lifetime.

BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies

BriaCell Therapeutics Corp (NASDAQ: BCTX) has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation (NASDAQ: INCY).  The Phase 1/2a combination study will evaluate BriaCell's lead candidate, Bria-IMT, with Incyte's retifanlimab & epacadostat to treat advanced breast cancer.

BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment

NEW YORK and VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the open recruitment and enrollment of their collaborative clinical study with Incyte. The Phase I/IIa combination study is designed to evaluate BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer.

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

The stock price of BriaCell Therapeutics Corp. (Nasdaq: BCTX) increased by 8.96% yesterday. This is why it happened.

BCTX Stock Price Increased 8.96%: Why It Happened

BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher on Wednesday after the company announced it is expanding its breast cancer platform into prostate, melanoma and lung cancers. The expansion includes Bria-Pros for prostate cancer, Bria-Mel for melanoma and Bria-Lung for lung cancer and the company anticipates commencing clinical trials for these therapies in 2022.

Why Shares Of BriaCell Therapeutics Surged Today

BriaCell Therapeutics Corp (NASDAQ: BCTX) has advanced its targeted oncology therapeutics into several novel immunotherapy cell lines, including - Bria-Pros for prostate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer. The company anticipates commencing clinical trials for these novel therapies in 2022.

BriaCell Extends Personalized Breast Cancer Immunotherapy To Prostate & Lung Cancer And Melanoma

BERKELEY, Calif. and VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces the advancement of its targeted oncology therapeutics into several novel immunotherapy cell lines: Bria-Pros™ for prostate cancer, Bria-Mel™ for melanoma, and Bria-Lung™ for lung cancer.

BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

Proceeds will be used to advance clinical and research and development pipeline and for general corporate purposes Proceeds will be used to advance clinical and research and development pipeline and for general corporate purposes

BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises

BERKELEY, Calif. and VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that CEO Dr. William V. Williams will host a corporate and clinical update call on Wednesday, June 16, 2021 at 4:30 p.m. ET.

BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET

BERKELEY, Calif. and VANCOUVER, British Columbia, June 07, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or “BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has closed its previously announced private placement of (i) 4,370,343 common shares at a purchase price of US$5.26, (ii) 800,000 pre-funded common share purchase warrants at a purchase price of US$5.25 (exercisable at any time after the date of issuance at an exercise price of US$0.01 per common share) and (iii) 5,170,343 warrants to purchase up to 5,170,343 common shares, which resulted in gross proceeds to BriaCell of US$27.2 million, before deducting offering expenses (the “Offering”). The Company expects to use the net proceeds of the private placement to further advance its research and development pipeline and for general corporate purposes.

BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement

BERKELEY, Calif. and VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or “BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has entered into definitive securities purchase agreements with accredited investors, which will result in gross proceeds to BriaCell of approximately US$27.2 million, before deducting placement offering expenses. BriaCell will issue 5,170,343 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock (“Warrant”) (or units consisting of one pre-funded common stock purchase warrant (“Pre-Funded Warrant”) and one Warrant, in lieu thereof). Each unit is being sold to the public at a price of US$5.26 (inclusive of the exercise price of the Pre-Funded Warrant, in the case of the units containing Pre-Funded Warrants). The Warrants have a five and one-half year term and an exercise price of US$6.19 per share. This private placement is expected to close on June 7, 2021, subject to customary closing conditions.

BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement

Shares of BriaCell Therapeutics Corp. more than doubled Wednesday on heavy volume, after the biotechnology company provided upbeat update on its breast cancer treatment. The stock soared 104% to pace all gainers on major U.S. exchanges, while trading volume spiked to 14.9 million shares, compared with the full-day average over the past 30 days of about 520,000 shares.

BriaCell stock more than doubles on heavy volume after upbeat update on breast cancer treatment

BriaCell Therapeutics Corp (NASDAQ: BCTX) has provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated advanced breast cancer patients. These women were treated with BriaCell's lead candidate, Bria-IMT, as monotherapy, and also in combination with checkpoint inhibitors, including Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) and Incyte Corporation's (NASDAQ: INCY) retifanlimab.

BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients

BERKELEY, Calif. and VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today provides an update on the overall survival (OS) data on its previously disclosed advanced breast cancer patients. These women were treated with BriaCell's lead candidate Bria-IMT™ as monotherapy and also in combination with checkpoint inhibitors, including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.) and Incyte's retifanlimab (manufactured and provided under a corporate collaboration with Incyte Corporation).

BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging' Tumor

BERKELEY, Calif. and VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer,   today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to participate in the following virtual conferences:

BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director

AUSTIN, Texas, April 21, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX-V: BCT) (“the Company”), to discuss the Company's targeted immunotherapies for breast cancer and its unique position as a clinical-stage biotech company.

BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com

BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has recently expanded its investor and media outreach platform in order to enhance communication with investors and increase investor awareness of and interest in the Company, its product candidates, and its clinical programs. The comprehensive program is expected to enhance BriaCell's dialogue with institutional and retail investors, industry analysts, and the investing public. The following IR and PR groups are currently engaged by the Company. It is important to disclose that BriaCell is unrelated and unaffiliated with each of the following entities, but the following firms and their clients may have an interest, directly or indirectly, in the securities of BriaCell.

BriaCell Announces Investor and Media Outreach Programs

BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has completed the sale of an additional 882,352 shares at the public offering price of US$4.24 per share pursuant to the underwriter's over-allotment option granted in connection with the Company's recent public offering, resulting in additional gross proceeds of approximately US$3.7 million. After giving effect to the full exercise of the over-allotment option, the total gross proceeds for the public offering increased to approximately US$28.7 million.

News for BriaCell Therapeutics Stock (BCTX)